Analyst firms · Deutsche Bank · ACAD

Deutsche Bank ACAD price target and rating history

ACADIA Pharmaceuticals Inc. (ACAD) · Health Care

Deutsche Bank rates ACADIA Pharmaceuticals Inc. (ACAD) Buy with a $35 price target, as of its latest action on May 21, 2025. It has published 4 rating actions on ACAD since December 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.

Current rating
Buy
Price target
$35
Median target, all firms
$31
Actions on ACAD
4

Deutsche Bank price target on ACAD

$35$29$22202420252026
Deutsche Bank price target on ACAD, each point a stated target, December 2023 to May 2025.

Every Deutsche Bank rating on ACAD

How other firms rate ACAD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSNeutral$23Oct 13, 2026
BofA SecuritiesBuy$29Mar 25, 2026
Wolfe ResearchOutperform$33Feb 24, 2026
MizuhoOutperform$35Feb 23, 2026

Questions about Deutsche Bank and ACAD

What is Deutsche Bank's price target for ACAD?
Deutsche Bank's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $35, from its action on May 21, 2025.
What is Deutsche Bank's rating on ACAD?
Deutsche Bank rates ACAD Buy, a bullish rating, as of May 21, 2025.
When did Deutsche Bank last change its view on ACAD?
On May 21, 2025, Deutsche Bank upgrades to Buy from Hold, price target $35.
How does Deutsche Bank's ACAD target compare with other analysts?
Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.

More ACAD rating histories

All Deutsche Bank ratingsACAD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.